Abstract

Introduction Native vessels are currently the preferred vascular conduits for procedures such as vascular bypass surgery. Artificial vascular grafts have limited applications, particularly for substituting smaller diameter vessels because of the increased incidence of stenosis, inflammatory response and tissue damage. Researches have, therefore, aimed to develop tissue-engineered vascular grafts that can be integrated into the cardiovascular system of patients. Tissue-engineered vascular grafts are expected to mimic the biological effect and mechanical properties of the native vascular tissue, as well as to maintain the long-term vascular repairing potential. The applications of biomaterials in tissue-engineered vascular graft approaches continue to expand at a rapid rate and have provided some clues as to how the design of grafts can be pursued in the future. The combination of stem cells and biomaterials has contributed to trigger tissue-engineered vascular graft remodelling. These grafts have demonstrated the ability to transform into living vascular tissue with repairing potential but the underlying mechanisms remain to be elucidated. In this review, we discuss the current state of the field of tissue-engineered vascular grafts and how the principles of biomaterials or nanobiomaterials are combined with stem cells to aid in the design of novel second-generation vascular grafts. Conclusion Vascular tissue engineering provides a potential solution to the shortage of vascular substitutes. A tissueengineered vascular graft incorporates into host vascular tissue and potentially solves the problems associated with conventional vascular grafts. The applications of nanobiomaterials may hold promise in the design of next-generation tissueengineered vascular grafts.

Highlights

  • Native vessels are currently the preferred vascular conduits for procedures such as vascular bypass surgery

  • Vascular tissue engineering provides a potential solution to the shortage of vascular substitutes

  • A tissueengineered vascular graft incorporates into host vascular tissue and potentially solves the problems associated with conventional vascular grafts

Read more

Summary

Conclusion

Many current advances on stem cell implantation within a vascular graft have been reviewed in this article Such approaches may produce engineered vascular tissue towards clinical applications. Various stem cells such as MSCs and EPCs can be introduced into vascular grafts. While the use of stem cells to create tissue-engineered vascular substitutes is still a developing field, it remains an exciting one that holds promise for the creation of vascular grafts for clinical applications. Abbreviations list ADSC, adipose-derived stem cell; AuNPs, gold nanoparticles; BDNF, brain-derived neurotrophic factor; BMC, bone marrow-derived cell; CStC, cardiac mesenchymal stromal cell; DV, decellularised blood vessel; EC, endothelial cell; ECM, extracellular matrix; eNOS, endothelial nitric oxide synthase; EPC, endothelial progenitor cell; iPS, pluripotent stem cell; MDSC, muscle-derived stem cell; MSC, Mesenchymal stem cells; PCL, poly(ε-caprolactone); PI3K, phosphoinositide 3-kinases; PMF, polyelectrolyte multilayer film; POSS-PCU, polyhedral oligomeric silsesquioxane modified polycarbonate ureaurethane; PU, Polyurethane; SDF-1α, stromal cell-derived factor-1α; SMC, smooth muscle cell; TEBV, tissue engineered blood vessel; TEVG, tissue engineering vascular graft; VE-cadherin, vascular endothelial cadherin; vWF, von Willebrand factor

Introduction
Discussion
Canine
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call